DVA vs. FMS: Which Dialysis Leader Is Better Positioned Now?
Focus Graphite Announces SEDAR+ Filing of the NI 43-101 Technical Report with the Updated Mineral Resource for the Lac Tetepisca Project
Focus Graphite Completes Final Major ESIA Technical Study, Advancing Lac Knife Toward Permitting
FMS and Home Dialysis: How 5008X Could Reset Demand
FMS Launches kinexus Digital Platform for Home Dialysis Care
Fresenius Medical Care launches kinexus worldwide, a unified digital platform to support home dialysis
Fresenius Medical Care launches first tranche of its share buyback program of up to EUR 600 million
Fresenius Medical Care highlights new renal research and innovation at ERA Congress 2026
Fresenius Medical Care announces new share buyback program with a total volume of around EUR 1 billion with phased execution over 12 months
Toronto Stock Exchange, Focus Graphite Inc., The View from the C-Suite
Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney care
Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney care
Fresenius Medical Care Reappoints Chief Financial Officer Martin Fischer
Fresenius Medical Care Reappoints Chief Financial Officer Martin Fischer
FMS Stock Rises Despite Q1 Earnings & Sales Miss, Margins Expand
Fresenius Medical Care AG (FMS) Q1 2026 Earnings Call Transcript
Fresenius Medical: The Undervaluation Is Getting Clearer
Fresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed
Fresenius Medical Care Posts Lower Net Profit on One-Off Costs
Fresenius Medical Care's revenue falls in Q1 as weak dollar takes toll
Is JB Hunt Transport Services (JBHT) 29.2% Overvalued After Q1 2026 Earnings Beat? EPS $1.49 vs $1.45 est; Revenue $3.06B vs $2.94B est - GF Score 87/100
Reviewing Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Bluejay Diagnostics (NASDAQ:BJDX)
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
Fresenius (FMS) is a Top-Ranked Value Stock: Should You Buy?
LivaNova (NASDAQ:LIVN) vs. Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Head to Head Comparison
Here's Why Fresenius (FMS) is a Strong Value Stock
FMS Stock Rises as Q4 Earnings & Sales Beat Estimates, Margins Expand
Fresenius Medical Care AG (FMS) Q4 2025 Earnings Call Transcript
Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band
Fresenius Medical Care Shares Drop After Outlook, U.S. Performance Underwhelms
Fresenius Medical Care's operating profit surges in Q4
Here's Why Fresenius (FMS) is a Strong Value Stock
FMS or MASI: Which Is the Better Value Stock Right Now?
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
3 Undervalued Medical Instrument Stocks Poised to Grow in 2026
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
Fresenius Medical Care AG (FMS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
FMS or MASI: Which Is the Better Value Stock Right Now?
Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
Here's Why Fresenius (FMS) is a Strong Momentum Stock
Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now
Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board
Here's Why Fresenius (FMS) is a Strong Value Stock
Fresenius Medical Care: 'Buy' Again Following A Peak In May
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
FMS Stock Rises as Q3 Earnings Beat Estimates, Revenues Gain Y/Y
Fresenius Medical Care AG (FMS) Q3 2025 Earnings Call Transcript
Fresenius Medical Care further accelerates organic revenue development and achieves an inflection in earnings growth, delivering 28% operating income growth in the third quarter of 2025